Retatrutide's Phase 2a in MASH/MASLD (Sanyal et al., Nat Med 2024) reported approximately 86% relative reduction in liver fat content at 12 mg/week the strongest hepatic-fat data among the incretin class
What blood sugar monitoring is recommended when taking both drugs
Endocrine disorders such as hyperthyroidism, pheochromocytoma, and carcinoid syndrome can cause excessive sweating
I will be an advocate for GLP-1 medications for the rest of my life
Side effects typically peak around weeks 6-8, then improve significantly by week 12
Saroglitazar, a PPAR-/ agonist, at a dosage of 4 mg qd significantly improved ALT, liver fat content (LFC), insulin resistance, and atherogenic dyslipidemia in patients with MASLD/MASH (NCT03061721)